Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber
MarketScreener,
ModelLEXINGTON, Mass. - (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for…
ModelLEXINGTON, Mass. - (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for…
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and…
LEXINGTON, Mass., February 01, 2022 BUSINESS WIRE Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company…
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and…
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and…